Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 5Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 5Polycystic Ovary Syndrome 4Pancreatic Neoplasms 2Neoplasm Metastasis 2Insulin Resistance 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Myeloid 1Racism 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia, Myeloid, Acute 1Infertility 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectum 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Brain Neoplasms 1Anovulation 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × Metformin × Clear all
NCT05828303 2025-04-01

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT02201381 2022-07-18

METRICS

Health Clinics Limited

Phase 3 Withdrawn
BreastCNSGastrointestinalGynecologic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡